Johnson & Johnson

JNJ Healthcare & Pharma 2/10 Low Risk
2/10
— 1 → 2 over 9 weeks
Sector avg: 2.8/10
▲
Risk Score Increased
1/10 → 2/10

Score changed by 1 point as of 2026-05-10.

What changed
▼ Cash coverage: 9.85x → 10.84x (improved)

Johnson & Johnson carries $41.4B in long-term debt, with $41.4B in scheduled principal maturities. DebtCanary scores JNJ at 2/10, suggesting manageable refinancing risk.

Maturity Schedule

Year 1 $2.0B Year 2 $3.2B Year 3 $3.1B Year 4 $2.2B Year 5 $2.7B Beyond 5 $28.3B
Period Amount Due % of Total
Year 1 (0-12 months) $2.0B 4.8%
Year 2 (12-24 months) $3.2B 7.8%
Year 3 (24-36 months) $3.1B 7.5%
Year 4 (36-48 months) $2.2B 5.2%
Year 5 (48-60 months) $2.7B 6.5%
Beyond 5 Years $28.3B 68.2%
Total Scheduled Maturities $41.4B 100.0%

Key Metrics

Total Long-Term Debt
$41.4B
Near-Term (12mo)
$2.0B
Interest Coverage
N/A
Debt/Equity
0.51
Cash Coverage
10.84x
Operating Income
N/A

Score Components

Component Value Weight
Near-Term Maturity Concentration 4.8% 30%
Interest Coverage Ratio N/A 25%
Debt-to-Equity Ratio 0.51 25%
Cash Coverage of Near-Term Debt 10.84x 20%

Recent SEC Filings

Material disclosures from Johnson & Johnson's most recent EDGAR filings. 8-K item labels indicate the type of event reported.

Date Form Details
2026-04-28 8-K Shareholder Vote
2026-04-22 10-Q Quarterly report
2026-04-14 8-K Earnings Results, Other Events
2026-03-11 DEFA14A Additional proxy materials
2026-03-11 DEF 14A Proxy statement
2026-02-11 10-K Annual report
2026-01-21 8-K Earnings Results
2025-10-22 10-Q Quarterly report

Related Companies

Pfizer
PFE
3/10
Debt: N/A 12mo: $3.0B
AbbVie
ABBV
4/10
Debt: $64.5B 12mo: $6.0B
Merck &
MRK
3/10
Debt: N/A 12mo: $2.6B
Eli Lilly
LLY
2/10
Debt: $29.5B 12mo: $781M
Bristol Myers Squibb
BMY
5/10
Debt: $44.1B 12mo: $2.0B
Amgen
AMGN
5/10
Debt: $57.3B 12mo: $4.6B
Gilead Sciences
GILD
3/10
Debt: $22.2B 12mo: $2.8B
Regeneron Pharmaceuticals
REGN
1/10
Debt: N/A 12mo: N/A

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Fiscal period end: 2026-03-29. Filing date: 2026-04-22. Data last fetched: 2026-05-10. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Partial.
View SEC EDGAR filings for Johnson & Johnson →